Kilitch Drugs (India) Limited Announces 1:1 Bonus Share Allotment
Kilitch Drugs (India) Limited's board approved allotment of 1,74,80,782 bonus equity shares in 1:1 ratio on March 25, 2026, with record date set as March 24, 2026. The bonus issue doubles the company's paid-up share capital from Rs. 17.48 crore to Rs. 34.96 crore, with new shares ranking pari-passu with existing equity shares.

*this image is generated using AI for illustrative purposes only.
Kilitch Drugs (India) Limited has announced a significant corporate action with its Board of Directors approving a bonus share allotment in a 1:1 ratio. The decision was taken during the board meeting held on March 25, 2026, marking a major milestone for the pharmaceutical company's shareholders.
Bonus Share Allotment Details
The company has approved the allotment of 1,74,80,782 bonus equity shares of Rs. 10 each to its shareholders. Under the 1:1 ratio scheme, shareholders will receive one bonus equity share of Rs. 10 each for every one equity share of Rs. 10 each currently held. The record date for determining eligible shareholders has been fixed as March 24, 2026.
The bonus equity shares will rank pari-passu in all respects with the existing fully paid-up equity shares of the company, ensuring equal rights and benefits for all shareholders.
Impact on Share Capital Structure
The bonus issue has resulted in a significant expansion of the company's equity base:
| Particulars | No. of Shares | Face Value (per share in Rs.) | Amount (in Rs.) |
|---|---|---|---|
| Paid-up Share Capital (Pre-Bonus Issue) | 17480782 | 10 | 174807820 |
| Paid-up Share Capital (Post Bonus Issue) | 34961564 | 10 | 349615640 |
The paid-up equity share capital has effectively doubled from Rs. 17.48 crore to Rs. 34.96 crore following the bonus share allotment.
Board Meeting Proceedings
The board meeting commenced at 10:30 hours and concluded at 12:05 hours on March 25, 2026. The decision was communicated to both BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The announcement was signed by Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited, bearing DIN: 00147876. This bonus share allotment represents the company's commitment to rewarding its shareholders while strengthening its equity structure for future growth initiatives.
How might this bonus share issuance affect Kilitch Drugs' stock liquidity and trading volumes in the coming quarters?
What strategic growth initiatives or expansion plans could Kilitch Drugs be preparing for with this strengthened equity structure?
Will the doubled share capital impact the company's dividend policy and payout ratios for future distributions?

































